Johannes Laengle

Johannes Längle is a surgical oncology and translational research entity led by Dr. Johannes Längle, an Associate Professor at the Medical University of Vienna. The organization specializes in the treatment of complex gastrointestinal and hepatobiliary malignancies while conducting advanced research into tumor immunology and immunotherapy. A primary focus of the entity is the induction of immunogenic cell death (ICD) to convert 'cold' tumors into 'hot' tumors, thereby enhancing the efficacy of immune checkpoint inhibitors. The research pipeline includes the development of oncolytic virus therapies, specifically utilizing modified Influenza A viruses to trigger anti-tumor immune responses. By integrating clinical surgical expertise with laboratory research, the entity aims to develop personalized multimodal treatment strategies for patients with advanced solid tumors. Johannes Längle operates both as a specialized medical practice in Vienna and as a prominent research group within the European oncology landscape.